Concurrently, advanced molecular therapeutics are emerging, including mitophagy inducers (e.g., urolithin A, nicotinamide riboside) to restore mitochondrial quality control (187, 188), gut microbiome engineering to reduce systemic inflammation (189), and innovative RNA therapeutics and gene circuits (e.g., olezarsen, the CHARM system) for long-term management of dyslipidemia (182, 183)
Who benefits most
Understanding why this happens and how to manage it can help you stay committed to your weight loss goals while your body adapts to the medication
Even though they treat the same things, each one can have its own side effects
16 The effect was large enough to matter clinically, not just statistically
However, they are still sensitive to moisture and light